RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REGENXBIO Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$7.15+0.23 (+3.25%)
Close on Oct 19, 2026
- Market cap
- $379.06M
- P/E (TTM)
- –
- Dividend yield
- –
REGENXBIO Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and royalty [Member] | $103.84M | $5.09M | $27.15M | $23.61M | $18.47M | $87.05M | $20.79M | $23.98M | $21.85M | $15.34M | $22.21M | $28.91M | 96.1% | +462.4% |
| AbbVie development milestone [Member] | $100.00M | – | – | – | – | – | – | – | – | – | – | – | 92.6% | – |
| Service [Member] | $4.18M | $1.30M | $3.19M | $6.13M | $2.89M | $1.96M | $426.00K | $215.00K | $449.00K | $278.00K | – | – | 3.9% | +44.4% |
| Total Service Revenue [Member] | $4.18M | $1.30M | $3.19M | $6.13M | $2.89M | $1.96M | $426.00K | $215.00K | $449.00K | $278.00K | – | – | 3.9% | +44.4% |
| Zolgensma and Itvisma Royalties [Member] | $3.84M | $5.05M | – | – | $18.42M | $16.99M | – | – | – | – | – | – | 3.6% | -79.2% |
| Nippon Shinyaku Services [Member] | $3.72M | $1.01M | $1.40M | $5.93M | $2.72M | $1.77M | – | – | – | – | – | – | 3.4% | +36.8% |
| Itvisma Royalties [Member] | $2.09M | $303.00K | – | – | – | – | – | – | – | – | – | – | 1.9% | – |
| Zolgensma Royalties [Member] | $1.75M | $4.75M | $23.53M | $23.59M | $18.42M | $16.99M | $20.66M | $23.87M | $21.76M | $15.21M | $21.87M | $28.36M | 1.6% | -90.5% |
| Other [Member] | $458.00K | $292.00K | $1.79M | $196.00K | $174.00K | $189.00K | $426.00K | $215.00K | $449.00K | $278.00K | – | – | 0.4% | +163.2% |
| Nippon Shinyaku Licenses [Member] | – | – | $2.92M | $0 | $0 | $69.98M | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Regenxbio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.